Literature DB >> 16081634

Somatostatin increases voltage-gated K+ currents in GH3 cells through activation of multiple somatostatin receptors.

Seung-Kwon Yang1, Helena C Parkington, Allan D Blake, Damien J Keating, Chen Chen.   

Abstract

The secretion of GH by somatotropes is inhibited by somatostatin (SRIF) through five specific membrane receptors (SSTRs). SRIF increases both transient outward (IA) and delayed rectifying (IK) K+ currents. We aim to clarify the subtype(s) of SSTRs involved in K+ current enhancement in GH3 somatotrope cells using specific SSTR subtype agonists. Expression of all five SSTRs was confirmed in GH3 cells by RT-PCR. Nystatin-perforated patch clamp was used to record voltage-gated K+ currents. We first established the presence of IA and IK type K+ currents in GH3 cells using different holding potentials (-40 or -70 mV) and specific blockers (4-aminopirimidine and tetraethylammonium chloride). SRIF (200 nM) increased the amplitude of both IA and IK in a fully reversible manner. Various concentrations of each specific SRTR agonist were tested on K+ currents to find the maximal effective concentration. Activation of SSTR2 and SSTR4 by their respective agonists, L-779,976 and L-803,087 (10 nM), increased K+ current amplitude without preference to IA or IK, and abolished any further increase by SRIF. Activation of SSTR1 and SSTR5 by their respective agonists, L-797,591 or L-817,818 (10 nM), increased K+ current amplitude, but SRIF evoked a further increase. The SSTR3 agonist L-797,778 (10 nM) did not affect the K+ currents or the response to SRIF. These results indicate that SSTR1, -2, -4, and -5 may all be involved in the enhancement of K+ currents by SRIF but that only the activation of SSTR2 or -4 results in the full activation of K+ current caused by SRIF.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16081634     DOI: 10.1210/en.2005-0696

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  9 in total

Review 1.  Pituitary somatostatin receptor signaling.

Authors:  Anat Ben-Shlomo; Shlomo Melmed
Journal:  Trends Endocrinol Metab       Date:  2010-02-09       Impact factor: 12.015

Review 2.  Somatostatin and dopamine receptor regulation of pituitary somatotroph adenomas.

Authors:  Anat Ben-Shlomo; Ning-Ai Liu; Shlomo Melmed
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

3.  Evaluation of a Novel DNA Vaccine Double Encoding Somatostatin and Cortistatin for Promoting the Growth of Mice.

Authors:  Xuan Luo; Zhuoxin Zu; Hasan Riaz; Xingang Dan; Xue Yu; Shuanghang Liu; Aizhen Guo; Yilin Wen; Aixin Liang; Liguo Yang
Journal:  Animals (Basel)       Date:  2022-06-08       Impact factor: 3.231

4.  Selenomethionine reduces visual deficits due to developmental methylmercury exposures.

Authors:  Daniel N Weber; Victoria P Connaughton; John A Dellinger; David Klemer; Ava Udvadia; Michael J Carvan
Journal:  Physiol Behav       Date:  2007-09-05

Review 5.  Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1--molecular pathways.

Authors:  Mehtap Cakir; Dorota Dworakowska; Ashley Grossman
Journal:  J Cell Mol Med       Date:  2010-11       Impact factor: 5.310

6.  The human brain somatostatin interactome: SST binds selectively to P-type family ATPases.

Authors:  Michael Solarski; Declan Williams; Mohadeseh Mehrabian; Hansen Wang; Holger Wille; Gerold Schmitt-Ulms
Journal:  PLoS One       Date:  2019-05-28       Impact factor: 3.240

Review 7.  Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World.

Authors:  Mayank Patel; Isabel Tena; Abhishek Jha; David Taieb; Karel Pacak
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-29       Impact factor: 5.555

Review 8.  Somatostatin and Somatostatin-Containing Interneurons-From Plasticity to Pathology.

Authors:  Monika Liguz-Lecznar; Grzegorz Dobrzanski; Malgorzata Kossut
Journal:  Biomolecules       Date:  2022-02-15

Review 9.  PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Franziska Briest; Patricia Grabowski
Journal:  Theranostics       Date:  2014-01-29       Impact factor: 11.556

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.